Search

Your search keyword '"Andrew, To"' showing total 25,676 results

Search Constraints

Start Over You searched for: Author "Andrew, To" Remove constraint Author: "Andrew, To" Journal blood Remove constraint Journal: blood
25,676 results on '"Andrew, To"'

Search Results

1. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

2. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

3. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

4. Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles

5. Risk prediction for clonal cytopenia: multicenter real-world evidence

6. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

7. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

8. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

10. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

11. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

12. Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity

13. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

15. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

17. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

18. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

21. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

23. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia

25. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

27. Failure of metabolic checkpoint control during late-stage granulopoiesis drives neutropenia in reticular dysgenesis

31. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

33. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

34. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

37. The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants

38. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

39. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

40. Race, rituximab, and relapse in TTP

41. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

43. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

45. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome

47. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

48. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

49. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

Catalog

Books, media, physical & digital resources